Rohto Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/10/07 11:46 UpdatedPrice Trend
2026/10/07 11:46 UpdatedPrice & Trading Details
2026/10/07 11:46 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/05 | ¥39.86 | ¥47.14 | +18.3% |
| 2026/05/12 | ¥30.36 | ¥26.41 | -13.0% |
| 2026/02/11 | ¥44.11 | ¥47.03 | +6.6% |
| 2025/11/12 | ¥24.91 | ¥26.03 | +4.5% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
MFS SERIES TRUST X-MFS International Intrinsic Value Fund
|
10.2M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.9M | +0.06% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.0M | +0.52% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.4M | +0.24% | |
|
Mercer Funds-Mercer Non-US Core Equity Fund
|
715.9K | +15.69% | |
|
EQ Advisors Trust-EQ/MFS International Intrinsic Value Portfolio
|
650.1K | 0.00% |
Dividend History 4Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥50 | +22.0% |
| 2025 | ¥41 | +32.3% |
| 2024 | ¥31 | +29.2% |
| 2023 | ¥24 | +17.1% |
| 2022 | ¥21 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥199,646M | ¥238,664M | ¥270,840M | ¥308,625M |
| Gross Profit | ¥116,170M | ¥137,421M | ¥157,285M | ¥174,939M |
| Operating Income | ¥29,019M | ¥33,964M | ¥40,052M | ¥38,943M |
| Pretax Income | ¥28,122M | ¥34,537M | ¥41,714M | ¥43,280M |
| Net Income | ¥21,127M | ¥26,377M | ¥30,936M | ¥31,006M |
| EPS | ¥92.34 | ¥115.29 | ¥135.21 | ¥135.44 |
| Operating Margin | 14.54% | 14.23% | 14.79% | 12.62% |
| Balance Sheet | ||||
| Total Assets | ¥274,876M | ¥309,677M | ¥346,175M | ¥421,875M |
| Total Equity | ¥178,398M | ¥209,568M | ¥246,323M | ¥260,093M |
| Total Liabilities | ¥96,478M | ¥100,109M | ¥99,852M | ¥161,782M |
| Cash | ¥72,791M | ¥79,951M | ¥89,210M | ¥77,161M |
| Interest-bearing Debt | ¥21,383M | ¥11,693M | ¥10,494M | ¥50,223M |
| Equity Ratio | 64.90% | 67.67% | 71.16% | 61.65% |
| D/E Ratio | 0.12 | 0.06 | 0.04 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥27,250M | ¥30,924M | ¥34,245M | ¥36,917M |
| Investing CF | -¥16,406M | -¥13,176M | -¥16,317M | -¥89,170M |
| Financing CF | ¥3,470M | -¥16,199M | -¥13,784M | ¥35,319M |
| Free CF | ¥15,922M | ¥21,016M | ¥25,333M | ¥26,356M |
| Efficiency | ||||
| ROE | 11.84% | 12.59% | 12.56% | 11.92% |
| ROA | 7.69% | 8.52% | 8.94% | 7.35% |
Latest IR Information
-
Notice Regarding Partial Correction of the Medium- to Long-Term Growth Strategy 2026
Partial corrections were made to the Medium- to Long-Term Growth Strategy 2026 as a rolling update. Financial forecasts were revised to present outlooks toward fiscal year 2031, amending the previous targets for fiscal year 2030. Dividend payout ratio expression was...
Read more -
"Medium- to Long-Term Growth Strategy 2026" – Rolling Update of "Rohto Group Medium- to Long-Term Growth Strategy 2025–2035" and Notice Regarding the 2031 Financial Forecast
Rolling update of the Medium- to Long-Term Growth Strategy 2025–2035 and publication of the 2031 financial forecast. 2031 net sales 464 billion yen, operating income 59.8 billion yen, operating margin 12.9%, overseas sales ratio 56%, dividend payout ratio 40%, ROE...
Read more -
Management Strategy Briefing 2026.10.02
Rolling update of the medium- to long-term growth strategy and disclosure of capital allocation policy. Strengthening business portfolios across eye care, skin care, oral supplements/ingestion, food, and medical segments, targeting net sales of 415 billion yen and operating income of...
Read more -
"Medium- to Long-Term Growth Strategy 2026" ～ Rolling Update of "Rohto Group Medium- to Long-Term Growth Strategy 2025–2035" and Announcement Regarding Financial Forecasts for Fiscal Year 2031 ～
Announced a rolling update of the medium- to long-term growth strategy and newly set financial forecasts for FY2031. Targets include net sales of 464 billion yen, operating income of 59.8 billion yen, operating margin of 12.9%, overseas sales ratio of...
Read more -
Notice of Share Buyback Status and Completion
Acquirements of treasury shares up to approximately 3.0 billion yen, acquisition period from 2026/8/7 to 2026/9/14, shares acquired: 1,038,600 ordinary shares, total amount about 2,999,998,289 yen. Acquisition completed via market purchases. At the time of the March 26, 2026 Board...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,290
Rating Score: 1.91 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods Japan, China, and internationally. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatological, gastrointestinal, and diagnostic drugs, as well as Chinese herbal medicines, and supplements. In addition, the company operates beauty counters that provide beauty and health services; and manufactures and sells diagnostic reagents, as well as provides investment management services; and contract development and manufacturing services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. The company was founded in 1899 and is headquartered in Osaka, Japan.
